| Value | ₹143.4 Cr |
|---|---|
| Execution period | 12 to 18 months |
BSE filing, NSE: NEULANDLAB. Summary written from the filing by ALFA Finder's alert engine.
Neuland Laboratories Ltd: key numbers
- Share price
- ₹19,700.00
- Market cap
- ₹25,275 Cr
- Revenue (annual)
- ₹2,023 Cr
- Net profit (annual)
- ₹364.0 Cr
- P/E (TTM)
- 50.8×Sector 45.9×
- Promoter holding
- 32.26%-0.36% QoQ
- FII holding
- 21.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neuland Laboratories Ltd
All →Neuland Laboratories Other Announcement
Neuland Laboratories notified loss of 100 share certificates by shareholder Madan Mohan Singh. The company requested issuance of an entitlement letter in lieu of the lost certificates.
Neuland Laboratories Board Meeting Date
Neuland Laboratories will hold a board meeting on November 3, 2026, to consider and approve the unaudited financial results for the quarter ended September 30, 2026.
Neuland Laboratories Business Update
Neuland Laboratories' Unit 3 manufacturing facility received an Establishment Inspection Report from the US FDA. The agency has officially closed the inspection.
Neuland Laboratories Other Announcement
Neuland Laboratories Ltd has submitted its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI Regulation 31.
Neuland Laboratories Promoter Selling (Off-Market)
Neuland Laboratories' promoter group, Davuluri Rohini Niveditha Rao and Davuluri Saharsh Rao, completed an off-market inter-se transfer of 10,000 shares via gift.
- Promoter stake change
- +0.07%
Neuland Laboratories Production Started
Neuland commissioned its first commercial peptide manufacturing module with 7,000L reactor capacity. Module two expansion is underway to meet rising customer demand for peptide APIs.
- peptide manufacturing reactor capacity
- 7000 L
Other financial results announcements
All →Peoples Investments Q2 FY27 Results: Net Profit ₹0 Cr
Peoples Investments approved unaudited standalone results for the quarter and half year ended 30 September 2026. The filing includes the statutory auditor's limited review report.
- Key figure
- Net profit ₹0 Cr
Alankit Q2 FY27 Results: Net Profit ₹7.4 Cr, Up 64.4% YoY
Alankit Ltd reported revenue from operations of ₹93.3 Cr (+16.5% YoY) and net profit of ₹7.4 Cr (+64.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹7.4 Cr · +64.4% YoY
Pajson Agro India H1 FY27 Results: Net Profit ₹12.6 Cr, Down 11.3% YoY
Pajson Agro India Ltd reported revenue from operations of ₹143.4 Cr (+21.1% YoY) and net profit of ₹12.6 Cr (-11.3% YoY) for H1 FY27.
- Key figure
- Net profit ₹12.6 Cr · -11.3% YoY
Borana Weaves Q2 FY27 Results: Net Profit ₹16.2 Cr, Down 3.0% YoY
Borana Weaves submitted unaudited results for the quarter and half year ended September 2026. Half-year revenue and profit both rose compared with the prior year.
- Key figure
- Net profit ₹16.2 Cr · -3.0% YoY
Shree Ganesh Bio-Tech (India) Q2 FY27 Results: Net Loss of ₹0.1 Cr
Shree Ganesh Biotech approved unaudited results for the half year ended September 2026. Half-year performance shows a net loss compared with last year's profit.
- Key figure
- Net loss ₹0.1 Cr
Krystal Integrated Services Q2 FY27 Results: Net Profit ₹18.7 Cr, Up 41.7% YoY
Krystal Integrated Services Ltd reported revenue from operations of ₹414.5 Cr (+46.3% YoY) and net profit of ₹18.7 Cr (+41.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹18.7 Cr · +41.7% YoY